Evaluation of Clinical Efficacy of Acupuncture in Improving Immune Response in Patients With Cervical Cancer

Not Applicable

Not yet recruiting

• Conditions: Cervical Cancer
• Interventions: Other: electropuncture

• Registration Number: NCT06591078
• Lead Sponsor: Ying Zhang

Brief Summary

In a prospective, multicenter, randomized, controlled study, patients with metastatic, recurrent, or persistent cervical cancer who were ineligible for surgery and/or radiotherapy were randomly assigned in a 1:1 ratio to either an experimental group or a control group." The control group was treated with apatinib combined with callizumab/callizumab combined with chemotherapy, and the experimental group was treated with electroacupuncture on the basis of the treatment. Anti-tumor efficacy, immune function efficacy, quality of life and safety were used as the outcome indicators.

Detailed Description

1. Study Design Types:

This was a prospective, multicenter, randomized controlled clinical study.

2. Random method:

This study used central randomization method. A total of 90 patients with recurrent/metastatic cervical cancer were enrolled and divided into 8 research centers. Patients were divided into control group (group A) and experimental group (group B) according to the pathological type, PD-L1 expression level, immunotherapy combined with targeted therapy/immunotherapy combined with chemotherapy as stratification factors at each research center. The block length was 6, and the allocation ratio was 1∶1.

3. Control methods:

This trial included a control group and an experimental group. The intervention measures of the experimental group included acupuncture + immunotherapy + targeted therapy/acupuncture + immunotherapy + chemotherapy. The intervention measures of the control group were immunotherapy + targeted therapy/immunotherapy + chemotherapy.

4. Sample size calculation:

This study intends to conduct preliminary exploratory research and use small samples for clinical observation. The sample size of each group of exploratory research should be more than 30 according to literature. This exploratory study intends to include 90 patients to be allocated to the experimental group and the control group

Study Timeline

• Study First Submitted: 2024-06-05
• Status Verified: 2024-09
• Study First Submitted QC: 2024-09-07
• Last Update Submitted: 2024-09-07
• Study First Posted: 2024-09-11
• Last Update Posted: 2024-09-11
• Study Start: 2024-09-15
• Primary Completion: 2026-11-01
• Study Completion: 2026-11-01

Recruitment & Eligibility

• Status: NOT_YET_RECRUITING
• Sex: Female
• Target Recruitment: 90

Inclusion Criteria

1. Patients with metastatic, recurrent or persistent cervical cancer including squamous cell carcinoma, adenosquamous cell carcinoma, that is not suitable for surgery and/or radiation therapy;

2. Age 18-70 years old;

3. Have at least one measurable lesion according to RECIST 1.1; Note: Measurable lesions are defined as those that can be accurately measured in at least one dimension (the longest diameter recorded by computed tomography (CT) scanning, magnetic resonance imaging (MRI) is ≥10mm; Lymph nodes must be ≥15mm on the short axis. Tumors within the previously irradiated area will be designated as "off-target" lesions unless progress is recorded at least 90 days after completion of radiation therapy or a biopsy is performed to confirm persistence.

4. The ECOG score is 0 or 1;

5. Life expectancy exceeds 3 months;

6. The patient's important organs function normally, as follows:

   Absolute neutrophil count (ANC) ≥1.5×10^9/L; Platelet count ≥80×10^9/L; Hemoglobin ≥90g/L;

   ④ Total bilirubin ≤1.5× upper limit of normal (ULN);

   ⑤ Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤2.5×ULN; Note: In patients with liver metastasis, AST and ALT levels were ≤5 ×ULN;

   ⑥ Creatinine ≤1.5×ULN or creatinine clearance ≥60 ml/min (Cockcroft-Gault formula);

   ⑦ Baseline albumin ≥28g/L;

7. Thyroid stimulating hormone (TSH) level ≤1×ULN; Note: Patients with free triiodothyronine [FT3] or free thyroxine [FT4] levels ≤1× ULN may be included.

8. Patients can sign written informed consent.

Exclusion Criteria

1. histopathological diagnosis of squamous cell carcinoma, adenosquamous carcinoma, or tumors other than adenocarcinoma;
2. have participated in another clinical trial, or completed another clinical trial within 4 weeks;
3. previous use of immune checkpoint inhibitors, including but not limited to other anti-PD-1 and anti-PD-L1 antibodies;
4. a known history of allergy to any component of carrilizumab preparations or other monoclonal antibodies;
5. Immunosuppressive drugs are currently required; Note: Prednisone > 10 mg/d or equivalent dose is prohibited within 2 weeks prior to administration of the study drug.
6. Patients with any active autoimmune disease or history of autoimmune disease, including but not limited to the following: hepatitis, pneumonia, uveitis, colitis (inflammatory bowel disease), pituitaritis, vasculitis, nephritis, hyperthyroidism and hypothyroidism, asthma patients requiring intermittent use of bronchodilators or other medical interventions; Note: Excluding vitiligo, resolved childhood asthma/atopic subjects.
7. Clinically significant cardiovascular disease, including but not limited to congestive heart failure (NYHA level > 2), unstable or severe angina, severe acute myocardial infarction within 1 year prior to enrollment, supraventricular or ventricular arrhythmias requiring medical intervention, or QT interval ≥470 milliseconds (women);
8. Arterial thrombosis or venous thrombosis occurs within 6 months; Hypertension medications do not adequately control hypertension (systolic blood pressure ≥140 mm Hg and/or diastolic blood pressure ≥90 mm Hg);

(10) proteinuria ≥ (++) or 24-hour urinary protein total > 1.0g; (11) Abnormal coagulation (INR > 2.0, PT > 16s), bleeding tendency or receiving thrombolytic or anticoagulant therapy; (12) has not recovered from an adverse event (other than hair loss) from prior administration (i.e. ≤ Grade 1 or baseline); (13) Known active central nervous system metastases; (14) Patients with prior invasive malignancy and any evidence of disease within the past 5 years; Note: Exceptions are basal cell carcinoma of the skin, squamous cell carcinoma of the skin, or cervical cancer in situ that has received potentially curative treatment.

(15) Have an active infection that requires systemic treatment; (16) A history of immunodeficiency, including seropositivity for human immunodeficiency virus (HIV) or other acquired or congenital immunodeficiency diseases; Hepatitis B virus (HBV) > 2000 IU/ml or DNA≥1×10^4/ml; Or hepatitis C virus (HCV) RNA ≥1×10^3/ml); (18) Received live vaccine within 4 weeks before the first trial treatment; Note: Inactivated virus vaccines against seasonal influenza are allowed. (19) Patients with suspected intestinal obstruction or risk of vagino-rectal fistula or vagino-vesical fistula; (20) Any other medical, mental, or social condition that the investigator believes may interfere with the subject's rights, safety, welfare, or ability to sign informed consent, cooperate, and participate in the study, or with the interpretation of the results.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
experimental group	electropuncture	1.Carrilizumab for injection; 200mg; Q14d; 2.Apatinib; 250mg Qd or Bid or chemotherapy; 3.electropuncture; 4/Q28d. Use up to 2 years/ patient disease progression(about 1 year)/ unacceptable toxic effects, use of prohibited therapies (such as antitumor therapy other than chemotherapy and beva or non-palliative radiotherapy)/ investigator's decision to discontinue the regimen/ or patient's withdrawal of consent treatment may be discontinued. If a patient with a confirmed complete response has received at least eight cycles of immunotherapy, including at least two cycles beyond a complete response, treatment will be discontinued.

Primary Outcome Measures

Name	Time	Method
objective remission rate	The patients were evaluated every 8 weeks ±2 weeks from the beginning of treatment until 40 weeks, and then every 12 weeks ±2 weeks until the end of treatment.	ORR refers to the proportion of patients whose tumor volume has shrunk to a predetermined value and can maintain the minimum time required. Cases with complete response (CR) and partial response (PR) were included.

Secondary Outcome Measures

Name	Time	Method
progression free survival	The patients were evaluated every 8 weeks ±2 weeks from the beginning of treatment until 40 weeks, and then every 12 weeks ±2 weeks until the end of treatment.	ORR refers to the proportion of patients whose tumor volume has shrunk to a predetermined value and can maintain the minimum time required. Cases with complete response (CR) and partial response (PR) were included.
overall survival	The patients were followed up until death or at least 2 years	From randomization to the time of death from any cause.
disease control rate	The patients were evaluated every 8 weeks ±2 weeks from the beginning of treatment until 40 weeks, and then every 12 weeks ±2 weeks until the end of treatment.	DCR refers to the proportion of patients whose tumor volume has shrunk or stabilized to a predetermined value and can maintain the minimum time required. Cases with complete response (CR), partial response (PR), and stable disease (SD) were included
Tumor marker	The patients were evaluated every 8 weeks ±2 weeks from the beginning of treatment until 40 weeks, and then every 12 weeks ±2 weeks until the end of treatment.	Tumor marker level of CA 125 and SCC.
Quality of life improvement	The patients were evaluated every 8 weeks ±2 weeks from the beginning of treatment until 40 weeks, and then every 12 weeks ±2 weeks until the end of treatment.	Use scale to evaluated the quality of life of patients.
Adverse events associated with immunotherapy and targeted therapy and their severity	The patients were evaluated every 8 weeks ±2 weeks from the beginning of treatment until 40 weeks, and then every 12 weeks ±2 weeks until the end of treatment.	NCI CTCAE V5.0 evaluation criteria for adverse events, including but not limited to skin reactions, pneumonia, colitis, nephritis, endocrine diseases, etc
Security Index	he patients were evaluated every 8 weeks ±2 weeks from the beginning of treatment until 40 weeks, and then every 12 weeks ±2 weeks until the end of treatment.	Blood, urine, stool routine, liver function (ALT, AST), kidney function (Cr, BUN) examination.